Drug costs: acquisition costs are critical but not the entire story of financial toxicity
BJU International · 2023
DOI: 10.1111/bju.16092 ↗Kurz gefasst
Editorial in der Zeitschrift BJU International, 2023. Verfasst von Deborah R Kaye. Beteiligte Einrichtung: Department of Surgery, Duke University, Durham, NC, USA. Hauptthemen laut MEDLINE: Financial Stress, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Duke University, Durham, NC, USA.
- Duke-Margolis Center for Public Policy, Duke University, Durham, NC, USA.
- Duke Clinical Research Institute, Durham, NC, USA.
- Duke Cancer Institute, Durham, NC, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Kaye, D. R. (2023). Drug costs: acquisition costs are critical but not the entire story of financial toxicity. BJU International. https://doi.org/10.1111/bju.16092
Vancouver
Kaye DR. Drug costs: acquisition costs are critical but not the entire story of financial toxicity. BJU International. 2023. doi:10.1111/bju.16092
BibTeX
@article{Kaye2023,
author = {Kaye, Deborah R},
title = {Drug costs: acquisition costs are critical but not the entire story of financial toxicity},
journal = {BJU International},
year = {2023},
doi = {10.1111/bju.16092}
}
EUVIMED